Top

Published in:

01-12-2021 | Idiopathic Pulmonary Fibrosis | PULMONARY FIBROSIS

Prognostic Significance of Pulmonary Artery to Aorta Ratio and Other CT Markers in Pulmonary Fibrosis With and Without Emphysema

Authors: F. Zeba, W. Yanning, J. Melek, F. Duan, M. K. Atalay, M. Jankowich, S. Rounds

Published in: Lung | Issue 6/2021

Abstract

Pulmonary hypertension (PH) is associated with decreased survival in patients with pulmonary fibrosis and combined pulmonary fibrosis and emphysema. Main pulmonary artery (PA) diameter and PA diameter/ascending aortic diameter (PA/AA) ratio, as measured on CT, have recently emerged as specific markers for PH. Our single-center retrospective study found that PA/AA ratio > 1 is associated with decreased survival in individuals with pulmonary fibrosis, with or without emphysema. Our study also describes markers of cardiac remodeling, and the echocardiographic diagnosis of PH in this patient population.

Wade RC, Simmons JP, Boueiz A, Gregory A, Wan ES, Regan EA, Bhatt SP, Han MK, Bowler RP, Crapo JD, Silverman EK, Washko GR, Dransfield MT, Wells JM (2021) Pulmonary artery enlargement is associated with exacerbations and mortality in ever-smokers with preserved ratio impaired spirometry (PRISm). Am J Respir Crit Care Med. https://doi.org/10.1164/rccm.202103-0619LECrossRefPubMed

Wells JM, Dransfield MT (2013) Pathophysiology and clinical implications of pulmonary arterial enlargement in COPD. Int J Chron Obstruct Pulmon Dis 8:509–521. https://doi.org/10.2147/COPD.S52204CrossRefPubMed

Ng CS, Wells AU, Padley SP (1999) A CT sign of chronic pulmonary arterial hypertension: the ratio of main pulmonary artery to aortic diameter. J Thorac Imaging 14(4):270–278. https://doi.org/10.1097/00005382-199910000-00007CrossRefPubMed

Truong QA, Massaro JM, Rogers IS, Mahabadi AA, Kriegel MF, Fox CS, O’Donnell CJ, Hoffmann U (2012) Reference values for normal pulmonary artery dimensions by noncontrast cardiac computed tomography: the Framingham heart study. Circ Cardiovasc Imaging 5(1):147–154. https://doi.org/10.1161/CIRCIMAGING.111.968610CrossRefPubMed

Raymond TE, Khabbaza JE, Yadav R, Tonelli AR (2014) Significance of main pulmonary artery dilation on imaging studies. Ann Am Thorac Soc 11(10):1623–1632. https://doi.org/10.1513/AnnalsATS.201406-253PPCrossRefPubMed

Terzikhan N, Bos D, Lahousse L, Wolff L, Verhamme KMC, Leening MJG, Felix JF, Gall H, Ghofrani HA, Franco OH, Ikram MA, Stricker BH, van der Lugt A, Brusselle G (2017) Pulmonary artery to aorta ratio and risk of all-cause mortality in the general population: the Rotterdam study. Eur Respir J 49(6):1602168. https://doi.org/10.1183/13993003.02168-2016CrossRefPubMed

Jankowich MD, Rounds SIS (2012) Combined pulmonary fibrosis and emphysema syndrome: a review. Chest 141(1):222–231. https://doi.org/10.1378/chest.11-1062CrossRefPubMed

Title: Prognostic Significance of Pulmonary Artery to Aorta Ratio and Other CT Markers in Pulmonary Fibrosis With and Without Emphysema
Authors: F. Zeba
W. Yanning
J. Melek
F. Duan
M. K. Atalay
M. Jankowich
S. Rounds
Publication date: 01-12-2021
Publisher: Springer US
Keywords: Idiopathic Pulmonary Fibrosis
Computed Tomography
Computed Tomography
Pulmonary Hypertension
Pulmonary Hypertension
Pulmonary Hypertension
Pulmonary Hypertension
Published in: Lung / Issue 6/2021
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI: https://doi.org/10.1007/s00408-021-00490-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2021

Twenty-Year Reflection on the Impact of World Trade Center Exposure on Pulmonary Outcomes in Fire Department of the City of New York (FDNY) Rescue and Recovery Workers

Diagnostic Performance of the Herder Model in Veterans Undergoing PET Scans for Pulmonary Nodule Evaluation

ETS1 Ameliorates Hyperoxia-Induced Alveolar Epithelial Cell Injury by Regulating the TGM2-Mediated Wnt/β-Catenin Pathway

Connective Tissue Growth Factor Single Nucleotide Polymorphisms in (Familial) Pulmonary Fibrosis and Connective Tissue Disease Associated Interstitial Lung Disease

Eosinophilic Chronic Obstructive Pulmonary Disease

FIZZ2 as a Biomarker for Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials